NM
MRSN

Newtyn Management’s Mersana Therapeutics MRSN Stock Holding History

Newtyn Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-28,000
Closed -$889K – 50
2023
Q3 		$889K Buy
+28,000
New +$1.33M 0.22% 39

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Newtyn Management's MRSN Position: Q4 2023 in Review

Newtyn Management sold out of Mersana Therapeutics (MRSN) in Q4 2023, closing a stake of 28,000 shares — an estimated $889K sold.

Newtyn Management first reported a position in MRSN in Q3 2023 and held it in 1 quarter. The position peaked at $889K in Q3 2023. 105 funds tracked by Wall St. Rank hold MRSN as of Q4 2023.

  • Newtyn Management reported no remaining Mersana Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Newtyn Management sold 28,000 Mersana Therapeutics shares in Q4 2023, an estimated $889K.
  • Newtyn Management first reported a position in Mersana Therapeutics in Q3 2023 and held it in 1 quarter.
  • Newtyn Management's Mersana Therapeutics position peaked at $889K in Q3 2023.
  • 105 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2023.

Based on Newtyn Management's 13F filing for Q4 2023, filed 14 Feb 2024.